

Table 1. Perioperative descriptors

	Aprotinin	Placebo	p Value
CABG<3	11	9	0.953
CABG>3	13	12	0.944
IMA/CABG	19	23	0.1079
CABG/valve	1	4	0.100
Valve (AVR/MVR)	2/2	0/0	0.040
OR time (min)	254±10	289±10	0.017
CPB time (min)	79±5	93±8	0.132
Sternal closure (min)	34±3	44±4	0.047
ICU time (hr)	66±11	169±72	0.125
Hospital stay (days)	11.1±0.9	15.4±3.2	0.15

Continuous data presented as mean ± standard error of the mean. *CABG*, Coronary artery bypass grafting; *IMA/CABG*, patients within coronary artery bypass group undergoing internal mammary artery grafting; *Valve (AVR/MVR)*, patients undergoing aortic valve repair or replacement or mitral valve repair or replacement; *OR time*, duration of operation; *CPB time*, duration of cardiopulmonary bypass; *Sternal closure*, time required from end of CPB until sternal wiring completed; *ICU time*, time spent in intensive care unit; *Hospital stay*, time from operation to discharge.

Table 2. Demographics

	Aprotinin	Placebo	p Value
Gender (M/F)	22/7	16/9	0.92
Age (yr)	62±1.8	65.8±1.5	0.10
CCU	3	3	0.9160
Aspirin duration (days)	653±202	835±268	0.60
Aspirin dosage (mg/day)	382±56	331±15	0.39
Last aspirin <24/24-48 hr	20/9	17/8	0.957

Continuous data presented as mean ± standard error of the mean. *CCU*, Coronary care unit admission immediately before the operation; *Last aspirin < 24/24-48 hr*, patients receiving aspirin within 24 hours or between 24 and 48 hours before the operation.

J Thorac Cardiovasc Surg 1994;107:554-61

Table 3. Total blood loss (mean ± standard error of the mean)

Blood loss	Aprotinin (n=29)	Placebo (n=25)	p Value
Total blood loss	1409.7±232.4	2765.8±248.0	0.0002
Total blood loss by surgeon (ml)			
Surgeon 1	1792±445.9 (n =14)	3017.8±447.0 (n =7)	
Surgeon 2	1406.4±293.5 (n =5)	2821.6±549.9 (n =7)	
Surgeon 3	755.3±20.5 (n =4)	2571.3±801.2 (n =3)	
Surgeon 4	955.0±176.5 (n =6)	2569.2±444.7 (n =8)	
Intraop. blood loss (ml)	503.6±53.0	1055.3±99.1	0.0001
Postop. blood loss (ml)	906.1±203.9	1710.4±110.7	0.0074
Blood loss in first 12 hr (ml)	465.9±145.6	792.8±110.7	0.0872

Table 4. Numbers of patients receiving transfusions of blood products*

Transfusion of blood products	Aprotinin (n=29)	Placebo (n=25)	p Value
Intraoperative: Yes/no	6/23 (20.7%)	12/13 (48%)	0.0309
Postoperative: Yes/no	17/12 (58.6%)	21/4 (84%)	0.0365
Total patients: Yes/no	17/12 (58.6%)	22/3 (88%)	0.0145

*Packed red blood cells, fresh frozen plasma, and platelets.

J Thorac Cardiovasc Surg 1994;107:554-61

**Table 5. Units of PRBCs transfused in patients receiving PRBCs
(mean±standard error of the mean)**

Period	Aprotinin (n=29)	Placebo (n=25)	p Value
Total PRBCs (U)	3.4±0.6 (n=16)	5.3±0.6 (n=22)	0.0398
Intraoperative PRBCs (U)	1.8±0.4 (n=6)	2.5±0.9 (n=12)	0.1083
Postoperative PRBCs (U)	3.0±4.3 (n=15)	4.3±0.6 (n=20)	0.0973

PRBCs, Packed red blood cells.

J Thorac Cardiovasc Surg 1994;107:554-61

**Table 6. Transfusion of blood products for all patients
(mean \pm standard error of the mean)**

Period	Aprotinin (n=29)	Placebo (n=25)	p Value
Intraoperative			
PRBCs (U)	0.4 \pm 0.1	1.2 \pm 0.3	0.01
FFP (U)	0.0 \pm 0.0	0.16 \pm 0.16	0.33
Platelets (U)	0.0 \pm 0.0	0.5 \pm 0.3	0.16
Postoperative			
PRBCs (U)	1.5 \pm 0.4	3.5 \pm 0.6	0.006
FFP (U)	1.3 \pm 0.5	1.4 \pm 0.4	0.89
Platelets (U)	0.9 \pm 0.6	1.2 \pm 0.5	0.70
Total			
PRBCs (U)	1.9 \pm 4.7	4.7 \pm 0.6	0.0007
FFP (U)	1.3 \pm 0.5	1.6 \pm 0.5	0.73
Platelets (U)	0.9 \pm 0.6	1.7 \pm 0.6	0.37

PRBC, Packed red blood cells; *FFP*, fresh frozen plasma.